ACP
ZYME icon

Acuta Capital Partners’s Zymeworks ZYME Stock Holding History

Acuta Capital Partners’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-80,143
Closed -$2.11M – 36
2025
Q4 		$2.11M Hold
80,143
– – 1.43% 16
2025
Q3 		$1.37M Sell
80,143
-3,512
-4% -$50.3K 1.41% 19
2025
Q2 		$1.05M Buy
83,655
+15,196
+22% +$181K 1.47% 20
2025
Q1 		$815K Buy
68,459
+1,219
+2% +$16.6K 0.95% 26
2024
Q4 		$984K Buy
+67,240
New +$940K 0.99% 26
2020
Q1 		– Sell
-70,500
Closed -$3.21M – 41
2019
Q4 		$3.21M Buy
70,500
+18,000
+34% +$654K 0.79% 28
2019
Q3 		$1.3M Buy
+52,500
New +$1.32M 0.94% 22

Other funds holding ZYME

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Acuta Capital Partners's ZYME Position: Q1 2026 in Review

Acuta Capital Partners sold out of Zymeworks (ZYME) in Q1 2026, closing a stake of 80,143 shares — an estimated $2.11M sold.

Acuta Capital Partners first reported a position in ZYME in Q3 2019 and held it in 7 quarters. The position peaked at $3.21M in Q4 2019. 212 funds tracked by Wall St. Rank hold ZYME as of Q1 2026.

  • Acuta Capital Partners reported no remaining Zymeworks position as of Q1 2026 after selling out during the quarter.
  • Acuta Capital Partners sold 80,143 Zymeworks shares in Q1 2026, an estimated $2.11M.
  • Acuta Capital Partners first reported a position in Zymeworks in Q3 2019 and held it in 7 quarters.
  • Acuta Capital Partners's Zymeworks position peaked at $3.21M in Q4 2019.
  • 212 funds tracked by Wall St. Rank held Zymeworks as of Q1 2026.

Based on Acuta Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.